Fecha de recepción: 20/02/2018 – Fecha de aceptación: 31/05/2018
Cárdaba-García ME, Izquierdo-Muñoz S, Izquierdo-Navarro MC, Sánchez-Sánchez MT
Servicio de Farmacia. Hospital Clínico Universitario de Valladolid. Valladolid (España)
____
Correspondencia:
María Elena Cárdaba García
Avda. Ramón y Cajal, 3
47003 Valladolid
Correo electrónico: mcardabag@saludcastillayleon.es
____
SUMMARY
Myasthenia gravis is an autoimmune disease refractory in 15-20% of cases to anticholinesterase and immunosuppressant drugs and to immunomodulatory therapies (intravenous immunoglobulin and plasmapheresis). For this reason, in patients diagnosed with refractory myasthenia gravis, it is necessary to consider other alternatives, as rituximab.
We present 3 cases of patients diagnosed with refractory myasthenia gravis and treated with rituximab, resulting in beneficial therapy for one of the subjects. This manuscript contributes to increase the published literature on the management of refractory myasthenia gravis, providing new data on the effectiveness of rituximab in this pathology.
Key Words: Myasthenia gravis, rituximab, autoimmune diseases, immunomodulation.
____
Download PDF: Rituximab en el tratamiento de la miastenia gravis refractaria